The best approach in motorized Parkinson‘s disease therapy is INTRADUODENAL LEVODOPA

Czech version

Published in: Cesk Slov Neurol N 2018; 81(5): 515
Category: Controversions

Sources

1. Wright BA, Waters CH. Continuous dopaminergic delivery to minimize motor complications in Parkinson‘s disease. Expert Rev Neurother 2013; 13(6): 719–729.

2. Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease. Eur J Neurol 2012; 19(12): 1502–1508.

3. Fernandez HH, Standaert DG, Hauser RA et al. Levodopa -⁠ carbidopa intestinal gel in advanced Parkinson‘s disease: final 12-month, open-label results. Mov Disord 2015; 30(4): 500–509.

4. Palhagen SE, Sydow O, Johansson A et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson‘s disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord 2016; 29 : 17–23.

5. Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson‘s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009; 24(10): 1468–1474.

6. Udd M, Lyytinen J, Eerola-Rautio J et al. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson‘s disease. Brain Behav 2017; 7(7): e00737.

7. Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson‘s disease: a systematic review. CNS Drugs 2016; 30(5): 381–404.

8. Zibetti M, Merola A, Artusi CA et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson‘s disease: a 7-year experience. Eur J Neurol 2014; 21(2): 312–318.